Medpace Holdings, Inc.

NasdaqGS MEDP

Medpace Holdings, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD 408.81 M

Medpace Holdings, Inc. Operating Income is USD 408.81 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 25.43% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Medpace Holdings, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 325.94 M, a 26.76% change year over year.
  • Medpace Holdings, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 257.12 M, a 29.37% change year over year.
  • Medpace Holdings, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 198.75 M, a 34.13% change year over year.
  • Medpace Holdings, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 148.17 M, a 21.64% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
NasdaqGS: MEDP

Medpace Holdings, Inc.

CEO Dr. August James Troendle M.D.
IPO Date Aug. 11, 2016
Location United States
Headquarters 5375 Medpace Way
Employees 5,900
Sector Health Care
Industries
Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Similar companies

QGEN

Qiagen N.V.

USD 45.57

-0.94%

IDXX

IDEXX Laboratories, Inc.

USD 418.63

-0.94%

ICLR

ICON Public Limited Company

USD 200.24

-8.14%

NEOG

Neogen Corporation

USD 12.00

-5.06%

RVTY

Revvity, Inc.

USD 120.73

-1.61%

LH

Laboratory Corporation of America Holdings

USD 234.50

0.17%

IQV

IQVIA Holdings Inc.

USD 197.96

-3.26%

CRL

Charles River Laboratories International, Inc.

USD 178.08

-6.34%

WAT

Waters Corporation

USD 404.93

1.26%

TWST

Twist Bioscience Corporation

USD 42.75

-1.91%

MTD

Mettler-Toledo International Inc.

USD 1.27 K

0.33%

StockViz Staff

January 15, 2025

Any question? Send us an email